Tscan Net Income From Continuing Ops from 2010 to 2026
| TCRX Stock | USD 1.06 0.05 4.50% |
Net Loss | First Reported 2020-06-30 | Previous Quarter -37 M | Current Value -35.7 M | Quarterly Volatility 10.2 M |
Check Tscan Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tscan Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 10.2 M, Interest Income of 14.6 M or Depreciation And Amortization of 3.6 M, as well as many indicators such as Price To Sales Ratio of 86.63, Dividend Yield of 0.0 or PTB Ratio of 0.66. Tscan financial statements analysis is a perfect complement when working with Tscan Therapeutics Valuation or Volatility modules.
Tscan | Net Income From Continuing Ops | Build AI portfolio with Tscan Stock |
The evolution of Net Income From Continuing Ops for Tscan Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Tscan Therapeutics compares to historical norms and industry peers.
Latest Tscan Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Tscan Therapeutics over the last few years. It is Tscan Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tscan Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Tscan Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (42,185,691) | |
| Coefficient Of Variation | (99.44) | |
| Mean Deviation | 35,451,247 | |
| Median | (13,658,000) | |
| Standard Deviation | 41,948,011 | |
| Sample Variance | 1759.6T | |
| Range | 113.8M | |
| R-Value | (0.85) | |
| Mean Square Error | 533.9T | |
| R-Squared | 0.72 | |
| Significance | 0.000019 | |
| Slope | (7,026,965) | |
| Total Sum of Squares | 28154.2T |
Tscan Net Income From Continuing Ops History
About Tscan Therapeutics Financial Statements
Tscan Therapeutics investors use historical fundamental indicators, such as Tscan Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tscan Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -114.7 M | -109 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.